Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Lung Neoplasms 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Rifaximin × Clear all
NCT04249622 2025-09-16

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Mayo Clinic

Phase 2 Terminated
20 enrolled 13 charts
Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT05502913 2023-10-02

Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer

Soroka University Medical Center

Phase 2 Recruiting
80 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡